First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.

JS De Bono, LA Mina, M Gonzalez, NJ Curtin, E Wang… - 2013 - ascopubs.org
2580 Background: BMN 673 is the most potent and specific inhibitor of PARP1/2 in clinical
development (IC50< 1nM). In tumors genetically dependent on DNA repair by homologous …
被引用次数：107 相关文章

[引用][C] First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors

B De, LA Mina, M Gonzalez, NJ Curtin… - 2013 ASCO Annual …, 2013 - eprints.ncl.ac.uk
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors - ePrints -
Newcastle University Newcastle University Toggle Main Menu Toggle Search Home Browse …